Evidence map›Paper›PMID 33101283›Full record

ReviewFrontiers in immunology2020

Neutrophil: A New Player in Metastatic Cancers.

Mengyue Wu, Mutian Ma, Zhenya Tan, Hong Zheng, Xia Liu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The Ly6gCancer communications (London, England) · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Single-cell analysis reveals potential therapeutic markers of peripheral blood mononuclear cells from bladder cancer patients.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  20. Chronic Stress-Induced and Tumor Derived SP1Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mengyue WuDepartment of Pathophysiology, Anhui Medical University, Hefei, China.
Mutian MaDepartment of Pathophysiology, Anhui Medical University, Hefei, China.
Zhenya TanDepartment of Pathophysiology, Anhui Medical University, Hefei, China.
Hong ZhengDepartment of Pathophysiology, Anhui Medical University, Hefei, China.
Xia LiuDepartment of Toxicology and Cancer Biology, Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, United States.

Funding

University of Kentucky Center for Cancer MetabolismP20GM121327 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jianhang Jia · 2017 to 2026
$25.0M
NIGMS NIH HHS P20 GM121327
6 · The paper itself

Abstract

The interaction between cancer cells and immune cells is important for the cancer development. However, much attention has been given to T cells and macrophages. Being the most abundant leukocytes in the blood, the functions of neutrophils in cancer have been underdetermined. They have long been considered an "audience" in the development of cancer. However, emerging evidence indicate that neutrophils are a heterogeneous population with plasticity, and subpopulation of neutrophils (such as low density neutrophils, polymorphonuclear-myeloid-derived suppressor cells) are actively involved in cancer growth and metastasis. Here, we review the current understanding of the role of neutrophils in cancer development, with a specific focus on their pro-metastatic functions. We also discuss the potential and challenges of neutrophils as therapeutic targets. A better understanding the role of neutrophils in cancer will discover new mechanisms of metastasis and develop new immunotherapies by targeting neutrophils.

Indexed as

Disease ProgressionAnimalsHumansImmune ToleranceImmunotherapyInflammationLymphocyte ActivationMacrophagesNeoplasm MetastasisNeoplasmsNeoplastic Cells, CirculatingNeutrophilsT-LymphocytesTumor Microenvironmentcirculating tumor cellsimmunosuppressionmetastasisneutrophilspre-metastatic nichetumor microenvironments

Identifiers

PMID33101283
PMCPMC7546851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.